The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

NCT04877821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Sintilimab
DRUG: Anlotinib
DRUG: Nab paclitaxel
DRUG: Carboplatin
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

Guangdong Provincial People's Hospital